Pharma downplays 25% tariff impact: US healthcare could feel the blow instead of India- what sector experts say
India’s pharma sector has downplayed the impact of US President Trump’s 25% tariff, warning instead of severe consequences for American healthcare. Industry leaders stressed India’s key role in supplying affordable medicines to the US and predicted shortages, higher costs, and a 3–5 year struggle for the US to find alternatives.
India’s pharma sector has downplayed the impact of US President Trump’s 25% tariff, warning instead of severe consequences for American healthcare. Industry leaders stressed India’s key role in supplying affordable medicines to the US and predicted shortages, higher costs, and a 3–5 year struggle for the US to find alternatives.
